The Ensign Group’s third quarter drew a positive market reaction despite missing Wall Street’s revenue and earnings per share expectations, as investors looked beyond headline numbers to underlying business momentum. Management attributed the quarter’s performance to continued gains in occupancy and skilled mix, with CEO Barry Port highlighting a “relentless patient-focused culture” and ongoing success in integrating new operations. The company’s clinical outcomes, validated by above-average quality ratings and lower staff turnover, played a significant role in attracting more complex cases and expanding relationships with managed care partners.
Is now the time to buy ENSG? Find out in our full research report (it’s free for active Edge members).
The Ensign Group (ENSG) Q3 2026 highlights:
- Revenue $1.48 billion vs S&P analysts’ estimates of $1.60 billion (14.5% year-on-year growth, 7.1% miss)
- EPS (GAAP) $1.76 vs analyst expectations of $1.81 (2.8% miss)
- Adjusted EBITDA $190.7 million vs analyst estimates of $186.2 million (12.9% margin, 2.4% beat)
- Revenue guidance The company slightly lifted its revenue guidance for the full year to $5.91 billion at the midpoint from $5.90 billion
- GAAP EPS guidance $7.98 at the midpoint for the full year, beating analyst estimates by 12.6%
- Operating margin 9.3%, up from 7.4% in the same quarter last year
- Sales volumes rose 13.1% year on year (15.1% in the same quarter last year)
- Market capitalization $10.65 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from The Ensign Group’s Q3 earnings call
- Ben Hendrix (RBC Capital Markets) asked about risks in entering the Florida market. CEO Barry Port cited the state’s busy litigation environment but described reimbursement and labor conditions as manageable, emphasizing the importance of local leadership in mitigating challenges.
- Ben Hendrix (RBC Capital Markets) followed up on the ability to handle higher-acuity patients in Florida. Port explained that strong relationships with health plans should accelerate the integration of complex care but acknowledged it will take time to build trust and referral volume.
- David MacDonald (Truist) asked about core business trends and the timeline for acquisitions to contribute. CFO Suzanne Snapper expects continued strong core performance and noted that newly acquired facilities typically take a year or more to become accretive.
- David MacDonald (Truist) queried about automation and AI initiatives. Port outlined several projects focused on clinical documentation efficiency and decision support, with the most excitement around tools that help clinicians gather and use patient information more effectively.
- Raj Kumar (Stephens) probed the sustainability of elevated skilled mix. Port attributed this to consistent clinical outcomes that earn trust from payers and referral partners, while Snapper noted growth across all payer types, not just one segment.
Catalysts in upcoming quarters
Looking ahead, the StockStory team will focus on (1) the pace of occupancy and skilled mix improvement in both legacy and newly acquired facilities, (2) evidence that operational and clinical integration is yielding margin and revenue gains, particularly in challenging markets like Florida and Texas, and (3) the rollout and impact of technology-driven efficiency initiatives. Continued discipline in acquisitions and leadership development will also be key drivers of future performance.
The Ensign Group currently trades at $188.25, up from $169.50 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
Our favorite stocks right now
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
